L. Roy Papp & Associates LLP Raises Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

L. Roy Papp & Associates LLP grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 48,916 shares of the medical research company’s stock after purchasing an additional 183 shares during the quarter. Thermo Fisher Scientific accounts for 3.0% of L. Roy Papp & Associates LLP’s investment portfolio, making the stock its 9th biggest position. L. Roy Papp & Associates LLP’s holdings in Thermo Fisher Scientific were worth $25,447,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Harbor Advisory Corp MA grew its stake in shares of Thermo Fisher Scientific by 8.1% in the fourth quarter. Harbor Advisory Corp MA now owns 11,201 shares of the medical research company’s stock worth $5,827,000 after purchasing an additional 839 shares in the last quarter. Stonebridge Financial Group LLC acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth about $103,000. Violich Capital Management Inc. increased its stake in Thermo Fisher Scientific by 13.7% during the 4th quarter. Violich Capital Management Inc. now owns 1,152 shares of the medical research company’s stock valued at $599,000 after buying an additional 139 shares during the period. Sapient Capital LLC raised its position in shares of Thermo Fisher Scientific by 35.9% during the 4th quarter. Sapient Capital LLC now owns 1,715 shares of the medical research company’s stock worth $893,000 after buying an additional 453 shares in the last quarter. Finally, Panoramic Capital Partners LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $218,000. 89.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

TMO has been the topic of several recent analyst reports. Barclays dropped their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Citigroup upped their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a report on Friday, January 31st. TD Cowen upped their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Finally, Evercore ISI cut their target price on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $658.00.

Thermo Fisher Scientific Stock Down 1.4 %

Shares of Thermo Fisher Scientific stock opened at $545.27 on Wednesday. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The stock has a 50 day moving average price of $547.81 and a two-hundred day moving average price of $571.95. The stock has a market capitalization of $208.57 billion, a P/E ratio of 32.99, a PEG ratio of 3.18 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific declared that its board has initiated a share repurchase plan on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase up to 2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the transaction, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen Williamson sold 9,825 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the transaction, the chief financial officer now owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. The trade was a 26.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 20,125 shares of company stock worth $11,231,699 over the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.